Top Markets
#1 DogBull DogBull +108.24%
#2 Siacoin Siacoin +44.70%
#3 The Bitcoin Bull The Bitcoin Bull +33.28%
#4 ADO Protocol ADO Protocol +28.67%
#5 Ontology Gas Ontology Gas +18.87%
#6 Cash Cat Cash Cat +14.00%
#7 UnifAI Network UnifAI Network +13.76%
#8 Akedo Akedo +12.45%
#9 Uniswap Uniswap +10.19%
#10 Apertum Apertum +9.92%
Coin of the day
DogBull DogBull
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
IX Biopharma Ltd. IX Biopharma Ltd.

IX Biopharma Ltd.

42C
Kedudukan dalam Saham #14769
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise... iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise headquartered in Singapore since its inception in 2004, focuses on the research, development, manufacturing, and commercialization of therapeutic solutions. The company targets acute and breakthrough pain, alongside various other health conditions, serving markets in Singapore, the United States, China, and Australia through its Specialty Pharmaceutical and Nutraceutical divisions. Its commercial offerings include Wafesil and Silcap, both indicated for male erectile dysfunction. Additionally, the company markets Xativa, a sublingual cannabidiol wafer, and Hypera, a sublingual tetrahydrocannabinol wafer, which address chronic pain, anxiety, and insomnia. iX Biopharma boasts an extensive product pipeline. Wafermine, a racemic ketamine sublingual wafer designed for complex regional pain syndrome and psychiatric conditions like depression, has successfully advanced through Phase 2 clinical trials. Other investigational candidates that have completed Phase 1 trials include iXB 120 for acute agitation, IXB-214 for complex regional pain syndrome, and IXB-314 for treatment-resistant depression. Furthermore, BnoX is currently undergoing Phase 1 evaluation for moderate to severe pain. In earlier development stages, iXB 401, a sublingual semaglutide wafer, is in pre-clinical development for Type 2 Diabetes and obesity. The pipeline also encompasses SL-NAD+, a sublingual NAD+ wafer engineered to boost the body's NAD+ levels, energy, and alertness; a distinct NAD+ product targeting sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafer for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer offering benefits for skin brightening and immunity.
Harga Saham
$0.36004668
Modal Pasaran
$393.64M
Perubahan (1 hari)
7.06%
Perubahan (1 tahun)
2,211.24%
Negara
SG
Perdagangan IX Biopharma Ltd. (42C)

Kategori

Healthcare
Sejarah harga saham bagi IX Biopharma Ltd. (42C)
Harga penutupan tertinggi: $0.36 pada 2026-09-01

Harga penutupan terendah: $0.33 pada 2015-07-01
Sejarah harga saham IX Biopharma Ltd. dari 2015 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) 106.54%
2025 446.22%
2024 -48.98%
2023 -64.13%
2022 -39.03%
2021 -15.40%
2020 14.66%
2019 26.68%
2018 -16.98%
2017 -23.25%
2016 -34.06%
2015 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 $171.67 -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 $168.32 32.21%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 $38.30 26.13%
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $21.26 19.67%
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 $214.46 22.68%
CH